Margarida Azevedo, MSc,  —

Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.

Articles by Margarida Azevedo

New Drug Candidate Shows Promise in Animal Model of Parkinson’s

University of Nebraska Medical Center and Longevity Biotech researchers demonstrated that LBT-3627, a novel drug candidate developed by the company, prevented nerve cell damage and protected dopamine-producing cells in a mouse model of Parkinson’s disease. The research paper, entitled “Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in…

Mitochondria Dysfunction Seen to Play a Role in Parkinson’s Disease

A novel physiological role for mitochondria with implications in the study of age-related diseases such as Parkinson’s has been described. Researchers found that mitochondrial dysfunction in proliferating human cells induces senescence growth arrest and causes cells to secrete distinct secretory phenotypes. The research paper, titled “Mitochondrial Dysfunction Induces Senescence with a Distinct…

Aspirin Molecule Targets Enzyme Active in Neurodegeneration

Researchers at the Boyce Thompson Institute and Johns Hopkins University have discovered that salicylic acid, the primary product from aspirin breakdown, binds to and blocks an enzyme thought to play a major role in neurodegenerative diseases, including Parkinson’s disease. The research paper, titled “Human GAPDH Is a Target of Aspirin’s Primary…

In Parkinson’s and Like Diseases, Cleansing Proteins Are Disrupted

Researchers have identified a specific protein involved in the functional upkeep of synaptic activity and detailed the process behind optimal neurotransmission — an activity whose breakdown is a defining feature of Parkinson’s and other neurodegenerative diseases. The research paper, entitled “Hsc70-4 Deforms Membranes to Promote Synaptic Protein Turnover by Endosomal Microautophagy” was published…

Countering Parkinson’s Treatment-induced Spasms

Scientists have identified a new strategy to attenuate one of the side effects — uncontrolled movement — caused by levodopa, the most effective treatment in the management of Parkinson’s disease symptoms. The study, entitled “M4 Muscarinic Receptor Signaling Ameliorates Striatal Plasticity Deficits in Models of L-DOPA-Induced Dyskinesia,” was published…